Articles On Prescient Therapeutics (ASX:PTX)
Title | Source | Codes | Date |
---|---|---|---|
PTX Solidifies Balance Sheet Further: Announces A$7 million Placement to Support Expanded Pipeline of Innovative Cancer Therapies
On 26 August 2020, Prescient Therapeutics Limited (ASX:PTX) announced that it has received firm commitments to raise A$7,046,084 (before costs) by way of a share placement of 128,110,611 fully paid ordinary shares to professional as well as... |
Kalkine Media | PTX | 3 years ago |
Sophisticated and professional investors line up to give Prescient Therapeutics cash
Special Report: Prescient Therapeutics has boosted its cash balance to $20.3m, leaving it well funded to research targeted personalised CAR-T cancer treatments following a successful $13.5m capital raising. Prescient Therapeutics (ASX:PTX)... |
Stockhead | PTX | 3 years ago |
Prescient Therapeutics raises $7 million to fund cancer treatment pipeline
Biotech Prescient Therapeutics (ASX: PTX) has successfully raised $7 million to fund an expanded pipeline of innovative cancer treatments. The clinical stage oncology company today announced it has received firm commitments from professiona... |
SmallCaps | PTX | 3 years ago |
Health Kick Podcast: Chemo’s diminishing role, the ‘personalised’ approach to cancer treatment and PTX’s CAR-T innovations
Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the pen and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Steven Yatomi-Clarke, CEO and managing direct... |
Stockhead | PTX | 3 years ago |
Prescient Therapeutics – ShareCafe Hidden Gems Webinar Presentation
ShareCafePrescient Therapeutics – ShareCafe Hidden Gems Webinar Presentation Presenter – Steven Yatomi-Clarke – CEO & MD – Prescient is focused on developing novel, personalised therapies against a range of cancers. Prescient’s unive... |
ShareCafe | PTX | 3 years ago |
Hidden Gems Webinar Recap – JHL, PTX, LNU
ShareCafeHidden Gems Webinar Recap – JHL, PTX, LNU We continue to unearth small-cap companies as part of our Hidden Gems webinar series. Catch up on the full webinar with presentations from Jayex Healthcare (ASX:JHL), Prescient Therapeut... |
ShareCafe | PTX | 3 years ago |
Prescient partners with global cancer heavyweight to develop new treatments
Prescient Therapeutics (ASX:PTX) has formed a cancer research partnership with the world-renowned Peter MacCallum Cancer Centre, ‘Peter Mac’, a leader in new clinical treatments for cancer to develop CAR-T cell therapy technologies. The res... |
Stockhead | PTX | 3 years ago |
Prescient Therapeutics teams up with Peter MacCallum Cancer Centre to advance CAR-T cancer therapy
Prescient Therapeutics (ASX: PTX) has moved closer to developing its unique CAR-T cancer technology after revealing a collaboration with the world-renowned Peter MacCallum Cancer Centre (Peter Mac) in Melbourne. The collaboration is expecte... |
SmallCaps | PTX | 3 years ago |
Prescient Therapeutics’ PTX100 Phase 1b Basket Study Progressing Well, Moves to Next Dose Level
Summary After demonstrating the safety at a dose of 1,000 mg/m2, Phase 1b study of PTX-100 will proceed to the increased dose of 2,000 mg/m2. Two patients from the first 500 mg/m2 cohort had reported with stable disease or better at the... |
Kalkine Media | PTX | 3 years ago |
Prescient gears up for growth with $6.5m raise as the race to cure cancer heats up
Special Report: Biotech company Prescient Therapeutics is advancing to next-stage trials for its personalised treatments for cancer and COVID-19 and has launched a capital raising for up to $6.5m via a Share Purchase Plan (SPP). The cash ra... |
Stockhead | PTX | 3 years ago |
Prescient Therapeutics Onboards Internationally Renowned CAR-T Expert Prof Phillip Darcy to Scientific Advisory Board
Australia based clinical-stage oncology company Prescient Therapeutics Limited (ASX:PTX) appointed globally renowned cancer and Chimeric Antigen Receptor-T (CAR-T) expert, Professor Phillip Darcy of Peter MacCallum Cancer Centre, to its Sci... |
Kalkine Media | PTX | 3 years ago |
Prescient Therapeutics’ Progresses to Next Dose Level in PTX-200 AML Phase 1b Study
Summary Prescient Therapeutics’ Phase 1b trial with PTX-200 in AML progresses to the next dose level of 35 mg/m2 PTX-200. Phase 1b study of PTX-200 at a dose of 25 mg/m2 demonstrated no dose-limiting toxicities and therapy was better to... |
Kalkine Media | PTX | 3 years ago |
Prescient Therapeutics to Raise A$6.5 million Via SPP to Advance Clinical & Pre-clinical Programs
Prescient Therapeutics (ASX:PTX), The ASX-listed biotechnology player developing targeted and personalised medicines for challenging cancers, announced a Share Purchase Plan (SPP) to raise nearly A$6.5 million. The Company intends to use th... |
Kalkine Media | PTX | 3 years ago |
Prescient Therapeutics launches new share purchase plan
Melbourne-based Prescient Therapeutics (ASX:PTX), a biotechnology company developing targeted and personalised medicines for cancer, has launched a $6.5 million capital raise. |
BiotechDispatch | PTX | 3 years ago |
Prescient Therapeutics’ Dazzling June Quarter Report, Achieved Significant Milestones
Summary In June 2020 quarter, Prescient added new assets in its belt with the most significant milestone of a next-generation immunotherapy platform ‘OmniCAR’. Prescient onboarded former Juno Executive Dr Allen Ebens, having a vast ... |
Kalkine Media | PTX | 3 years ago |
Remarkable! Assets of Prescient Selected for COVID-19 Antiviral Testing Program by Doherty Institute
Clinical stage oncology company Prescient Therapeutics Limited (ASX:PTX) notified that two of its assets had been selected as Group 1 priority candidates for a COVID-19 antiviral testing program by Doherty Institute in Melbourne. Both asset... |
Kalkine Media | PTX | 3 years ago |
Prescient Therapeutics assets chosen for COVID-19 antiviral test program
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has revealed two of its assets have been selected as group one priority candidates for a COVID-19 antiviral testing program in Melbourne, Victoria. This is unexpected news to... |
SmallCaps | PTX | 3 years ago |
10 at 10: These ASX stocks are starry-eyed this morning
Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte... |
Stockhead | PTX | 3 years ago |
Get Acquainted with Prescient Therapeutics’ Next Generation Immunotherapy Platform
Prescient Therapeutics Limited (ASX:PTX) is a clinical-stage oncology company developing personalised medicine approaches to cancer, including cellular as well as targeted therapies. The targeted therapies include two drug candidates, PTX-2... |
Kalkine Media | PTX | 3 years ago |
Prescient Therapeutics has path forward as they look to future of cancer treatments
|
Proactive Investors | PTX | 3 years ago |
Another Golden Feather in Prescient’s Hat, PTX-200 Receives Two US Patents
Well-known for developing breakthrough targeted and personalised medicines approaches to treat cancer, Prescient Therapeutics Limited (ASX:PTX) has been gaining attention on the back of its recent achievements. Building on this momentum, on... |
Kalkine Media | PTX | 3 years ago |
Prescient Therapeutics licenses Pennsylvania and Oxford university technologies to create universal cell therapy platform
The company’s goal is to harness OmniCAR’s innate adaptability and control to develop novel cell therapy products for new indications, and improve the cost, time and of effectiveness of delivering cell therapy products. |
Proactive Investors | PTX | 3 years ago |
Closing Bell: Today’s biggest small cap movers on the ASX
A quick wrap of the key winners and losers on Monday, June 1. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potentially market-moving announcements during the day. WINNERS CODE COMPANY PRICE... |
Stockhead | PTX | 3 years ago |
Prescient Therapeutics obtains two key licenses to develop ‘chimeric immune receptor platform’ OmniCAR
Biotech company Prescient Therapeutics (ASX: PTX) emerged from a trading halt this morning to unveil two significant licenses related to its universal immune receptor technology platform, currently in the pre-clinical development stage. In... |
SmallCaps | PTX | 3 years ago |
Prescient Therapeutics obtains two key licences to develop ‘chimeric immune receptor platform’ OmniCAR
Biotech company Prescient Therapeutics (ASX: PTX) emerged from a trading halt this morning to unveil two significant licences related to its universal immune receptor technology platform, currently in the pre-clinical development stage. In... |
SmallCaps | PTX | 3 years ago |
Trading Places: The latest small explorer Tolga Kumova has sunk his teeth into
Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve been keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f... |
Stockhead | PTX | 3 years ago |
Prescient Now the Outright Owner of IP Resulting from CAR-T Collaboration
ASX-listed Australia based clinical-stage oncology player Prescient Therapeutics Limited (ASX:PTX) is engaged in the development of new drugs that demonstrate significant promise as potential innovative therapies for the treatment of challe... |
Kalkine Media | PTX | 3 years ago |
Prescient’s Clinical Trials for PTX100 Progressing at Speed; Proceeds to Next Stage
Clinical trials are being shuttered in increasing numbers in Australia because of the challenges posed by COVID-19; however, one clinical-stage oncology company Prescient Therapeutics Limited (ASX:PTX) continues to march ahead. The Company... |
Kalkine Media | PTX | 4 years ago |
Prescient Therapeutics advances development of PTX-100
Prescient Therapeutics (ASX:PTX) says the Phase 1b study of PTX-100 will proceed to the next dose level following successful completion of the first cohort of patients and demonstrating acceptable safety. |
BiotechDispatch | PTX | 4 years ago |
Prescient Therapeutics proceeds to next stage of PTX-100 drug trial for patients with advanced cancers
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has confirmed a phase 1b basket study of its cancer drug PTX-100 will proceed to the next dose level following successful completion on the first cohort of patients and achie... |
SmallCaps | PTX | 4 years ago |
Cancer clinical trials continue as others are shut down on COVID-19 fears
Clinical trials are being shuttered in increasing numbers in Australia because of the risks posed by COVID-19, but two companies this morning say theirs are moving ahead at speed. Prescient Therapeutics (ASX:PTX) says its phase 1b study of... |
Stockhead | PTX | 4 years ago |
Prescient Reports March 2020 Quarterly Update; Cash Reserves at $8.2 Million
Australian based clinical-stage Oncology company Prescient Therapeutics Limited (ASX:PTX), recently reported operating highlights and financial outcomes for the March quarter 2020. The Company is engaged in the development of new drugs tha... |
Kalkine Media | PTX | 4 years ago |
Prescient Therapeutics’ Operations Remain Unscathed by COVID-19 Pandemic
The Coronavirus has become a health threat across the globe and as per World Health Organization (WHO) until now this pandemic has resulted in over 72,744 deaths and infected more than 1,282,931 worldwide in just a few months (8 April 2020,... |
Kalkine Media | PTX | 4 years ago |
Prescient Therapeutics- A Shining Star Amidst Cancer Space
1 in 6 deaths is due to cancer As per World Health Organization, Cancer is the 2nd major cause of death globally, and is responsible for an ~9.6 million deaths in 2018. Worldwide, about one in six deaths is owing to cancer. Demand for eff... |
Kalkine Media | PTX | 4 years ago |
Prescient Therapeutics Update on Half Year Financials: Positive Clinical Development Continued
Prescient Therapeutics Limited (ASX: PTX) is an Australian based clinical-stage oncology company which is into small molecule drug development focused on new drugs for the treatment of a range of cancers that have become resistant to front... |
Kalkine Media | PTX | 4 years ago |
Prescient Therapeutics Update on Half Year Financials: Positive Clinical Development Continued
Prescient Therapeutics Limited (ASX: PTX) is an Australian based clinical-stage oncology company which is into small molecule drug development focused on new drugs for the treatment of a range of cancers that have become resistant to front... |
Kalkine Media | PTX | 4 years ago |
Cancer Wars Part 1: These are the ASX small cap drugmakers that want to conquer cancer
The health sector was the most successful sector on the ASX in 2019. Various small caps made several breakthroughs including with nerve damage and macular degeneration. While cancer remains one fish that has yet to be fried there are small... |
Stockhead | PTX | 4 years ago |
Prescient Therapeutics' Remarkable 2019 Journey
|
Kalkine Media | PTX | 4 years ago |
Health: PainChek reveals exactly how much its grown in 2019; and says there’s more to come next year
It’s fair to assume PainChek (ASX:PCK) shareholders are a happy bunch with a 12-month share price rise of 413 per cent. The rise of the pain-detection app company began in late April thanks to a $5m investment from the Morrison government.... |
Stockhead | PTX | 4 years ago |
Prescient Therapeutics receives encouraging efficacy results for leading cancer drug candidate PTX-200
Oncology company Prescient Therapeutics (ASX: PTX) has unveiled news of a high response rate to its PTX-200 leading drug candidate from a Phase 2 breast cancer trial. The news comes less than 2 weeks since Prescient announced positive inter... |
SmallCaps | PTX | 4 years ago |
Prescient Therapeutics (ASX:PTX) reports positive results in breast cancer drug trial
Prescient Therapeutics (PTX) has reported a high response rate from its Phase 2a clinical trial for breast cancer All of the evaluable patients responded to the PTX-200 drug, with the disease completely eradicated in some patients All bu... |
themarketherald.com.au | PTX | 4 years ago |
Prescient Takes Another Leap Forward, Unveils Promising Interim Results from PTX-200 Phase 1b Ovarian Cancer Trial
Clinical stage oncology company engaged in developing personalised medicine approaches including targeted and cellular therapies to beat cancer, Prescient Therapeutics (ASX: PTX) has been gaining industry limelight for its advancing clinica... |
Kalkine Media | PTX | 4 years ago |
Biotech stocks to watch in 2020
Whether a day trader or a long-term investor, we often examine research released by industry experts, brokers and analysts with a view to uncovering the next big thing. The more complex the sector, the more we are likely to rely on informat... |
FinFeed | PTX | 4 years ago |
Prescient Therapeutics confirms positive early results in drug trial for patients with platinum-resistant ovarian cancer
Oncology specialist company Prescient Therapeutics (ASX: PTX) has announced positive interim data from a Phase 1b safety study of its lead drug PTX-200 in women with recurrent or persistent platinum-resistant ovarian cancer. Conducted at th... |
SmallCaps | PTX | 4 years ago |
Prescient Collaborates with Carina Biotech in Expansion into Exciting CAR-T Therapies
Prescient Therapeutics Limited (ASX: PTX) develops personalised medicine approaches to address mutations that cause cancer. The Company employs a targeted therapy approach to target individual tumour variability rather than the conventional... |
Kalkine Media | PTX | 4 years ago |
Prescient Unveils Encouraging Results: Eradication of Cancer in Three Acute Myeloid Leukemia Patients
Clinical-stage Oncology Company, Prescient Therapeutics Limited (ASX: PTX), that develops personalised medicine approaches to address mutations causing cancer. Prescient’s deep product pipeline include 2 clinical stage drugs with multiple s... |
Kalkine Media | PTX | 4 years ago |
Prescient trials show total eradication of cancer
Shares in Prescient Therapeutics Limited (ASX:PTX) surged 50% on Wednesday after the clinical stage oncology company developing personalised medicine approaches to cancer released promising news in relation to its Phase 1b study in patients... |
FinFeed | PTX | 4 years ago |
Prescient Therapeutics expands study after completely eradicating cancer in patients
Cancer drug developer Prescient Therapeutics (ASX: PTX) is expanding its Phase 1b study in patients with acute myeloid leukemia (AML) after three patients were completely eradicated of the disease. The clinical stage company had been treati... |
SmallCaps | PTX | 4 years ago |
Health: Fricken lasers shrink ovarian cancer (also look good on sharks)
For a certain generation of investors the word ‘laser’ is indelibly tied to a Dr Evil reference. Over the last two years Invion (ASX:IVX) has been valiantly working against this association, and today says its lasers (not attached to the he... |
Stockhead | PTX | 4 years ago |
10 at 10: These ASX stocks are getting amongst it this morning
Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte... |
Stockhead | PTX | 4 years ago |